MENU
Anatomy
Anesthesiology
Biochemistry
Biomedical Informatics
Biophysics
Cell Biology
Clinical Cases
Dentistry
Dermatovenerology
Emergency Medicine
Family Medicine
Forensic Medicine
Gynecology and Obstetrics
Histology and Embryology
History of Medicine
Human Genetics
Hygiene
Infectious Diseases
Internal Medicine
Medical Deontology and Philosophy
Medical Psychology
Microbiology and Immunology
Neurology
Occupational Medicine
Oncology
Ophthalmology
Orthopaedics
Otorhinolaryngology
Pathology
Pathophysiology
Pediatrics
Pharmacology and Experimental Toxicology
Physical and Rehabilitation Medicine
Physiology
Psychiatry
Radiology
Social Medicine
Surgery
Toxicology
Research papers
Clinical research paper
Preclinical research paper
Sponsored articles
Archive » 2012 » 2 » | Archive » Medical field » Fields » Oncology » Archive » Medical field » Fields » Pharmacology and Experimental Toxicology »

Trends of Usage and Development of Biological Drugs for Treatment of Malignancies

 
Abstract:

This post is also available in: enEnglish slSlovenščina (Slovenian)

Biological drugs mostly differ from classical agents in their molecular mass, complex three-dimensional structure, molecular heterogeneity and imunogenity. Moreover, the most important aspect of these agents is their capability of targeting specific signal molecules, consequently causing no or less damage to the non-targeted tissue. Hence, this fact led to widely accepted belief that biopharmaceutical drugs are among the safest on the market. During the conduct of different studies researchers found new physiological roles of targeted molecules that were previously unknown. These findings overruled the assumption about targeted therapy being selective and specific and made the researchers question their safety. Over the last two decades, there has been an exponential growth of investments into the development of new molecular therapies. Hence, there are a lot of studies underway and more targeted biologic drugs registered every year.

Authors:
Kelc Robi, Topolovec Janja

Keywords:
biological drugs, signal molecules, target proteins, inflammatory mediators, monoclonal antibody

Cite as:
Med Razgl. 2012; 51: 145–57.
© 2022 Društvo Medicinski razgledi | Na vrh strani / To top ↑